MedTrace Logo

Rheumatoid Arthritis Satisfaction Outcome Research

NCT03703817 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 421

Last updated 2021-03-16

Study results available
· View outcomes & findings →

Summary

RA satisfaction OR: This study aim to compare treatment satisfaction and quality of life between patients who have been using tofacitinib citrate and patients who have been using adalimumab for 6 months or more and less than 2 year in RA treatment of rheumatoid arthritis.

Conditions

Sponsors & Collaborators

  • Yonsei University

    collaborator OTHER

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-02
Primary Completion
2020-03-12
Completion
2020-03-12

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03703817 on ClinicalTrials.gov